Regenxbio Inc (NASDAQ: RGNX) on Monday, plunged -2.43% from the previous trading day, before settling in for the closing price of $7.41. Within the past 52 weeks, RGNX’s price has moved between $7.15 and $28.80.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 72.63%. The company achieved an average annual earnings per share of 21.59%. With a float of $44.85 million, this company’s outstanding shares have now reached $49.53 million.
Let’s determine the extent of company efficiency that accounts for 344 employees. In terms of profitability, gross margin is 39.46%, operating margin of -289.09%, and the pretax margin is -283.37%.
Regenxbio Inc (RGNX) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Regenxbio Inc is 9.47%, while institutional ownership is 90.25%. The most recent insider transaction that took place on Dec 30 ’24, was worth 148,504. Before that another transaction happened on Oct 01 ’24, when Company’s Director sold 10,000 for $10.11, making the entire transaction worth $101,052. This insider now owns 11,286 shares in total.
Regenxbio Inc (RGNX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.17 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 21.59% per share during the next fiscal year.
Regenxbio Inc (NASDAQ: RGNX) Trading Performance Indicators
Regenxbio Inc (RGNX) is currently performing well based on its current performance indicators. A quick ratio of 3.05 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.00.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.03, a number that is poised to hit -1.13 in the next quarter and is forecasted to reach -0.96 in one year’s time.
Technical Analysis of Regenxbio Inc (RGNX)
Looking closely at Regenxbio Inc (NASDAQ: RGNX), its last 5-days average volume was 1.17 million, which is a jump from its year-to-date volume of 0.72 million. As of the previous 9 days, the stock’s Stochastic %D was 21.48%. Additionally, its Average True Range was 0.70.
During the past 100 days, Regenxbio Inc’s (RGNX) raw stochastic average was set at 1.26%, which indicates a significant decrease from 2.80% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 62.58% in the past 14 days, which was lower than the 71.38% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.29, while its 200-day Moving Average is $12.87. However, in the short run, Regenxbio Inc’s stock first resistance to watch stands at $7.42. Second resistance stands at $7.61. The third major resistance level sits at $7.72. If the price goes on to break the first support level at $7.12, it is likely to go to the next support level at $7.01. Now, if the price goes above the second support level, the third support stands at $6.82.
Regenxbio Inc (NASDAQ: RGNX) Key Stats
Market capitalization of the company is 337.27 million based on 49,545K outstanding shares. Right now, sales total 90,240 K and income totals -263,490 K. The company made 24,200 K in profit during its latest quarter, and -59,600 K in sales during its previous quarter.
